TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline on Preclinical Alzheimer Cognitive Composite (PACC) Component Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in RBANS Index Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrence and change in severity of treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Compliance and Tolerability of Medication Regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of falls and injurious falls
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Testosterone <=0.5ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Development of protective levels of antibody to hepatitis B virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants hospitalized for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Doses of therapies that comprise guideline directed medical therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Artery Systolic Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differentiation of tumor B lymphocytes from normal B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of total to HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psychological parameters
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants receiving 3 intra-arterial injections of melphalan
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incremental area under the blood glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of syllable correctly recognized
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Priapic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent correct
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional Independence Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Stroke Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brunnstrom Motor Recovery Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of clinical remission (<= 3 stools per day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Renal blood flow and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Autonomic Classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical bed recurrence-free survival (SB-RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Mean Milligrams of Dietary Sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Hour 0 Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of participants experiencing treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: HIV/disease prevention knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: behavioral intentions
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: HIV risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Gross Motor Function Measure (GMFM-66) - Section E
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of fibroatheromas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral muscle function assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Virological parameters of the HIV reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunological parameters of the HIV reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Mothers With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Mothers With Adverse Events (AEs) During Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Infants With Adverse Events (AEs) During Follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of children with abnormal speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ADL Staircase
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete cure of target great toenail
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Volume and perimeter measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Agitation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cesarean section scar defect shapes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Average from All Biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Complete Wound Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of Adagrasib monotherapy and combination therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the number of TB patients being actively followed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the MIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uNTx (Corrected by Creatinine) < 50 Nmol/mmol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endurance measured by six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed measured by ten-meter maximum walk speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength measured by handgrip strength tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance assessed by Time Up and Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of individuals demonstrating disclosure decision-making capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Positive and Negative Affect Scale - Short Form (PANAS-SF) Positive Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Positive and Negative Affect Scale - Short Form (PANAS-SF) Negative Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite incidence of major adverse cardiac, cerebrovascular and thromboembolic events
Endpoint domain: Mortality/survival
Primary endpoint: Inflammatory response measured by cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of severe sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiovascular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunization efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical pleth index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in WOMAC score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Satisfaction of postmenopausal women
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum plasma concentration (Cmax) of BAY14-2222
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration vs time curve AUC(0-tlast) of BAY14-2222
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-naïve Participants With HIV-RNA Levels <50 c/mL at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Treatment-naïve Participants With HIV-RNA Levels <50 c/mL at 48 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Treatment-naïve Participants With HIV-RNA Levels <50 c/mL at 96 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: miR-155 expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: development of aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Performance Score on a Cognitive Test Battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EuroQol five dimensions questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ VAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-weighted Summed Pain Intensity Difference (SPID48)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CRP Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy of Satraplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in number of episodes of lower UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement of QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urgency Severity Scale (USS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta values for 24h ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in WOMAC A Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Resolution of Apnea, Bradycardia and Desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in colonization rates and infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum tolerated dose and recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Life space assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PSA Decline of >= 50% (PSA50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive Value of R-IPI at Diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Change in mean sitting systolic blood pressure (MSSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Unsolicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Serious AEs or Medically Attended AEs (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with drug related Adverse Events (AEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects achieving HIV-1 ribonucleic acid (RNA) suppression < 50 copies per milliliter (c/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal tissue necrosis or inflammatory immune cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasmin-antiplasmin complex (PAP complex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of Mycophenolic acid concentration-controlled therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Treatment Emergent Adverse Events (TEAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Biomechanical stability of the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical stability of the cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety/tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Glenoid Component Placement (Inclination and Version)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Glenoid Component Placement (AP and SP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of >= grade 2 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Effect of Bupropion for Methamphetamine Dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent of Self Test Fingerstick Blood Glucose Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ADAMTS-13 enzyme levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ADAMTS-13 activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: vWF antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: vWF activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hopkins Verbal Learning Test-Revised (HVLT-R) Total Trials 1-3
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Drinking Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alcohol-related Consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Lens Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain associated with endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDSS change categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in MusiQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average 24-h pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth rate of primary and metastatic tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diffuse myocardial fibrosis (elevated extracellular volume fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in pre-operative staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of Amlodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCinf of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative 1-year mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Patient Specific Functional Scale (PSFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: mortality differences between group who received early BCG and late BCG
Endpoint domain: Mortality/survival
Primary endpoint: mortality by parental scar status
Endpoint domain: Mortality/survival
Primary endpoint: Heart Rate (Bradycardia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Short Term Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physiological dead space
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Combined Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of blood thyroid stimulating hormone (TSH) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percent change in urinary GAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients using the online reminder tool
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose-limiting Toxicity
Primary endpoint: Area under plasma concentration-time curve from time zero to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-curve from time zero to time of last quantifiable concentration [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion at discharge and six weeks post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with autograft or delayed primary closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of all hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Tidal volume reduction to 4 mL/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining pH to ± 20% of baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining PaCO2 to ± 20% of baseline values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CMAI Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPV8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVV8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation of BiodentineTM and formocresol pulpotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic evaluation of BiodentineTM and formocresol pulpotomies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rates of the study end-points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Voltage fluctuation resulting from brain activity after visual stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Voltage fluctuation resulting from brain activity after auditory stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Voltage fluctuation resulting from brain activity after visual and auditory stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of access to the central portion of the femoral artery (Zone III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of access to the Zone III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Severity of symptoms and functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving ≥ 50% but < 75% Improvement in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving IGA Mod 2011 0 or 1 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Local-Progression Free Survival (LPFS)
Endpoint domain: Mortality/survival
Primary endpoint: In-stent binary angiographic restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TKI adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean-24h-ABP < 130/80 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular echocardiographic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Obstetric parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Reduction in epileptiform EEG discharges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Inter-rated agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pain Score of Four or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes